Inflammatory neuropathies

Current Neurology and Neuroscience Reports

Volumn 5, Issue 1, 2005, Pages 66-71

  Briemberg, Hannah R ^b   Amato, Anthony A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; LIPOPOLYSACCHARIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ATELECTASIS; BLOOD CLOTTING DISORDER; BLOOD COMPONENT THERAPY; BONE MARROW TRANSPLANTATION; CAMPYLOBACTER JEJUNI; CEREBROSPINAL FLUID CYTOLOGY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CLINICAL OBSERVATION; DECUBITUS; DEEP VEIN THROMBOSIS; DEMYELINATING NEUROPATHY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SUBSTITUTION; ELECTROPHYSIOLOGY; ENTERITIS; GUILLAIN BARRE SYNDROME; HEART INFARCTION; HEPATITIS B; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOREFLEXIA; IMMUNOMODULATION; KIDNEY FAILURE; LEUKEMIA; LYMPHOMA; MOLECULAR MIMICRY; MONOCLONAL IMMUNOGLOBULINEMIA; NERVE BIOPSY; NERVE CONDUCTION; NERVE FIBER DEGENERATION; OPHTHALMOPLEGIA; PARAPROTEINEMIA; PATHOPHYSIOLOGY; PLASMAPHERESIS; PNEUMONIA; PREVALENCE; PROGNOSIS; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; STROKE; SURAL NERVE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TREATMENT OUTCOME;

EID: 16344378065     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-005-0026-z     Document Type: Review

References (37)

1. Jacobs BC, Rothbarth PH, van der Meche N, et al.: The spectrum of antecedent infections in Guillain Barre syndrome. A case-control study. Neurology 1998, 51:1110-1115.
2. Ogawara K, Kuwabara S, Mori, et al.: Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000, 48: 24-631.
3. Brannagan TH 3rd, Zhou Y: HIV-associated Guillain-Barre syndrome. J Neurol Sci 2003, 208(1-2):39-42.
4. Wen PY, Alyea EP, Simon D, et al.: Guillain-Barre syndrome following allogeneic bone marrow transplantation. Neurology 1997, 49:1711-1714.
5. Lasky T, Terracciano GJ, Magder L, et al.: The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998, 339:1797-1802.
6. Pritchard J, Mukherjee R, Hughes RA: Risk of relapse of Guillain-Barre syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunization. J Neurol Neurosurg Psychiatry 2002, 73:348-349.
7. Wijdicks EF, Fletcher DD, Lawn ND: Influenza vaccine and the risk of relapse of Guillain-Barre syndrome. Neurology 2000, 55:452-453.
8. Oh SJ, Kurokawa K, de Almeida DF, Ryan HF Jr, Claussen GC: Subacute inflammatory demyelinating polyneuropathy. Neurology 2003, 61:1507-1512.
9. Rees JH, Thompson RD, Smeeton NC, Hughes RA: Epidemiological study of Guillain-Barre syndrome in south east England. J Neurol Neurosurg Psychiatry 1998, 64:74-77.
10. Fletcher DD, Lawn ND, Wolter TD, Wijdicks EF: Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation. Neurology 2000, 54:2311-2315.
11. Hiraga A, Mori M, Ogawara K, et al.: Differences in patterns of progression in demyelinating and axonal Guillain-Barre syndromes. Neurology 2003, 61:471-474.
12. Kuwabara S, Asahina M, Mori M, et al.: Two patterns of clinical recovery in Guillain-Barre syndrome with anti-GM1 antibody. Neurology 1998, 51:1656-1660.
13. Yuki N, Taki T, Inagaki F, et al.: A bacterium lipopolysaccaride that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 1993, 178:1771-1775.
14. Hafer-Macko CE, Sheikh KA, Li CY, et al.: Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996, 39:625-635.
15. Hafer-Macko CE, Hsieh ST, Li CY, et al.: Acute motor axonal neuropathy: an antibody mediated attack on axolemma. Ann Neurol 1996, 40:635-644.
16. Hughes RA, Wijdicks EF. Barohn R, et al.: Practice parameter: immunotherapy for Guillain-Barre syndrome. Report of the Quality of Standard Subcommittee of the American Academy of Neurology. Neurology 2003, 61:736-740.
17. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group: Randomised trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain-Barre syndrome. Lancet 1997, 349:225-230.
18. van Koningsveld R, Schmitz PI, van der Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomized trial. Lancet 2004, 363:192-196.
19. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force: Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Adacemy of Neurology AIDS Task Force. Neurology 1991, 41:617-618.
20. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course and recommendations for diagnostic criteria. Arch Neurol 1989, 46:878-884.
21. Schimdt B, Toyka KV, Kiefer R, et al.: Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 1996, 19:474-487.
22. Kieseier BC, Dalakas MC, Hartung HP: Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 2002, 59(Suppl 6):S7-S12.
23. Dyck PJ, O'Brien PC, Oviatt KF, et al.: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982, 11:136-141.
24. Dyck PJ, Daube J, O'Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314:461-465.
25. Hahn AF, Bolton CF, Pillay N, et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 1996, 119:1055-1066.
26. Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 1996, 119:1067-1077.
27. Dyck PJ, Litchy WJ, Kratz KM, et al.: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994, 36: 38-845.
28. Mendell JR, Barohn RJ, Freimer ML, et al.: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001, 56: 45-449.
29. Hughes R, Bensa S, Wilson H, et al.: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:195-201.
30. Radziwill AJ, Steck AJ, Renaud S, Fuhr P: Distal motor latency and residual latency as sensitive markers of anti-MAG polyneuropathy. J Neurol 2003, 250:962-966.
31. Katz JS, Saperstein DS, Gronseth G, et al.: Distal acquired demyelinating symmetric neuropathy. Neurology 2000, 54:615-620.
32. Saperstein DS, Katz JS, Amato AA, Barohn RJ: Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001, 24:311-324.
33. Gorson KC, Ropper AH, Weinberg DH, Weinstein R: Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 2001, 24:778-786.
34. Dalakas MC, Quarles RH, Farrer RG, et al.: A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996, 40: 92-795.
35. Dyck PJ, Low PA, Windebank AJ, et al.: Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991, 325: 482-1486.
36. Nobile-Orazio E, Meucci M, Baldini L, et al.: Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000, 123: 10-717.
37. Saperstein DS, Amato AA, Wolfe GI, et al.: Multifocal acquired demyelinating sensory and motor neuropathy. The Lewis-Sumner syndrome. Muscle Nerve 1999, 22:560-566.